IN VITRO AND IN SILICO SCREENING OF 6-FLUORO-3-(PIPERIDIN-4-YL) BENZO[D]ISOXAZOLE DERIVATIVES FOR BLOOD BRAIN BARRIER PERMEABILITY
Blood Brian Barrier (BBB) is a physiologically and metabolically significant membrane that enables and limits the uptake of specific molecules by the brain, thus preserving the homeostasis within the Central nervous System (CNS).All the Antipsychotic drugs are permeable across the BBB, however most of First/Second generation antipsychotic drugs employed in the medical field are known to be associated with Extrapyramidal symptoms (EPS). Hence our interest is devoted in the development of novel antipsychotic drugs that ameliorate psychosis with least frequency of EPS. In our previous study the newly synthesized molecules, 6-fluoro-3-(piperidin-4-yl) benzo[d]isoxazole derivatives (S1-S4) which have shown positive alterations in chemical properties and biological activities demonstrating significant neuroleptic properties. However possibility and efficiency of these synthesized molecules to penetrate through the Blood Brain Barrier will be of utmost importance to determine its treatment efficacy. In this line of investigation, in the present study, in silico and in vitro methods are employed to evaluate the permeability in comparison with that of standard antipsychotic drugs, Resperidone and Haloperidol. In vitro analysis was done by Parallel artificial Membrane Permeability Assay (PAMPA) in PBS, where in permeability of S2(8.3x10-6) and S3(6.6x10-6) molecules showed higher permeability than known standards Warfarin(1x10-6), Resperidone(2.3x10-6) and Haloperidol(3.5x10-6), and the molecules exhibited recovery above 50% and in silico studies also showed high permeability rate with all the synthesized molecules. Thus we can conclude that, all the synthesized molecules have the potential to develop into promising Antipsychotic drugs.
Key words: Antipsychotics, Blood Brain Barrier, EPS, PAMPA, In silico
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).